The PARAMOUNT phase III trial demonstrated that pemetrexed continuation maintenance significantly reduced the risk of disease progression ( hazard ratio = @ ) and death ( hazard ratio = @ ) versus placebo in patients with advanced nonsquamous non-small-cell lung cancer .